Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló, 149-153, Barcelona 08036, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló, 149-153, Barcelona 08036, Spain; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain; Hematopathology Unit, Hospital Clínic of Barcelona, University of Barcelona, Villarroel 170, Barcelona 08036, Spain.
Hematol Oncol Clin North Am. 2020 Oct;34(5):795-807. doi: 10.1016/j.hoc.2020.05.002. Epub 2020 Jul 22.
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with heterogeneous clinical behavior molecularly characterized by the constitutive overexpression of cyclin D1 and deregulation of different signaling pathways. SOX11 expression determines an aggressive phenotype associated with accumulation of many chromosomal alterations and somatic gene mutations. A subset of patients with the SOX11-negative leukemic non-nodal MCL subtype follows an initial indolent clinical evolution and may not require treatment at diagnosis, although eventually may progress to an aggressive disease. We discuss the genetic and molecular alterations with impact on the cancer hallmarks that characterize the lymphomagenesis of the 2 MCL subtypes.
套细胞淋巴瘤(MCL)是一种成熟 B 细胞肿瘤,具有异质性的临床行为,分子特征为 cyclin D1 的组成性过表达和不同信号通路的失调。SOX11 的表达决定了一种侵袭性表型,与许多染色体改变和体细胞基因突变的积累有关。具有 SOX11 阴性白血病非结外 MCL 亚型的患者亚组最初表现为惰性临床演变,在诊断时可能不需要治疗,尽管最终可能进展为侵袭性疾病。我们讨论了对癌症特征具有影响的遗传和分子改变,这些改变特征性地描述了 2 种 MCL 亚型的淋巴瘤发生。